Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

Guidelines recommend, as first-line treatment for hypertension, a diuretic or the combination of diuretic ± ACE inhibitor. Prevention of Stroke in Patients.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

(p for noninferiority = 0.01)

Blood Pressure and Lipid Trials: Rationale, Importance and Design

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

LEADER trial: Primary Outcome

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

The Anglo Scandinavian Cardiac Outcomes Trial

Why wasn’t a beta-blocker tested as first-line therapy?

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Adjusted relative mortality risk

Outcomes with trisodium citrate 30% vs heparin as catheter-locking solution (all catheters) in patients on hemodialysis Variable TSC, n (%) Heparin, n.

Creatinine clearance (mL/min) n All-cause mortality (%)

Emerging Mechanisms in Glucose Metabolism

Prevalence of statin and beta-blocker use by clinical presentation

ALLHAT: What Outcomes Would Have Been Expected?

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

PREMIER: Rate of hypertension at 18 months

How to Optimize TAVR Outcomes

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta- Analysis of Randomized Controlled Trials Ahmed Mahmoud, MD, Islam.

Jun M, et al. Lancet 2010 Epub May 10

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Fung TT, et al. Circulation 2009;119:

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

Mancini JG, et al. Am J Cardiol.

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.

Cystatin C levels and risk of death from all causes

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Volume 371, Issue 9627, Pages (May 2008)

Patient characteristics: American vs Canadian transplant patients

Berger JS, et al. JAMA 2009;301:

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

Cause of death Treatment-arm events, % (n=45 054)

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

MATRIX: Radial vs. Femoral

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

Absolute mortality difference Change in LVEF from baseline

Christian Madelaire et al. JCHF 2018;6:

FIELD: Primary outcome

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Presentation transcript:

Meta-analysis of trials comparing beta blockers with other antihypertensives Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30 MI 1.02 0.93–1.12 All-cause mortality 1.03 0.99–1.08 Lindholm LH, et al. Lancet 2005; available at: http://www.lancet.com.

Atenolol vs other antihypertensives Outcome Relative risk with atenolol 95% CI Stroke 1.26 1.15–1.38 MI 1.05 0.91–1.21 All-cause mortality 1.08 1.02–1.14 Lindholm LH, et al. Lancet 2005; available at: http://www.lancet.com.

Nonatenolol beta blockers vs other antihypertensives Outcome Relative risk with beta blockers 95% CI Stroke 1.20 0.30–4.71 MI 0.86 0.67–1.11 All-cause mortality 0.89 0.70–1.12 Lindholm LH, et al. Lancet 2005; available at: http://www.lancet.com.

Combination of beta blockers plus diuretics vs other antihypertensives Outcome Relative risk with beta blockers 95% CI Stroke 1.09 0.98–1.21 MI 1.00 0.81–1.22 All-cause mortality 0.97 0.89–1.05 Lindholm LH, et al. Lancet 2005; available at: http://www.lancet.com.